-+ 0.00%
-+ 0.00%
-+ 0.00%
Adicon Terminates Crown Bioscience Acquisition After Regulatory Approvals Fail to Materialize
Share
Listen to the news
Adicon Terminates Crown Bioscience Acquisition After Regulatory Approvals Fail to Materialize
  • Adicon Holdings' planned acquisition of 100% of Crown Bioscience International will not proceed following termination of the share purchase agreement.
  • The buyer and seller mutually terminated the agreement effective November 13, 2026, because regulatory approvals were not obtained by the extended deadline.
  • The board expects no material adverse impact on the group's business operations or financial position.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicon Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413153), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending